## CLX: Clorox Company (The) - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%); PEG 3.35 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Understanding the Setup: (CLX) and Scalable Risk**
- Source: Stock Traders Daily | 20251217T231400 | Somewhat-Bearish | Relevance: 100%
- This article analyzes Clorox Company (CLX), indicating a near-term neutral sentiment amidst mid and long-term weakness. It highlights an exceptional 22.5:1 risk-reward short setup, signaling potential downside, and outlines three distinct AI-generated trading strategies for different risk profiles.

**2. Clorox (CLX) Rating: Citigroup Lowers Price Target to $109.00**
- Source: GuruFocus | 20251217T214001 | Somewhat-Bearish | Relevance: 100%
- Citigroup has reaffirmed its Neutral rating on Clorox (CLX) but has reduced its price target from $120.00 to $109.00, indicating a downward revision of 9.17% in the expected valuation. This adjustment by analyst Filippo Falorni follows a series of similar price target reductions by other firms like JP Morgan, Wells Fargo, and Morgan Stanley in recent months. Despite these adjustments, the average target price from 17 analysts suggests a potential upside for Clorox, and GuruFocus estimates a fair value for the stock above its current trading price.

**3. Clorox (NYSE:CLX) Price Target Lowered to $109.00 at Citigroup**
- Source: MarketBeat | 20251217T144308 | Somewhat-Bearish | Relevance: 100%
- Citigroup has lowered its price target for Clorox (NYSE:CLX) to $109 from $120, maintaining a "neutral" rating. This implies an 8.1% upside, despite the company recently beating EPS estimates but experiencing an 18.9% year-over-year revenue decline and setting FY2026 EPS guidance. Several other brokerages have also adjusted their price targets and ratings on Clorox.

**4. Jim Cramer on Clorox: “It’s a Terrific Day to Own Clorox (CLX)”**
- Source: Insider Monkey | 20251217T122800 | Somewhat-Bullish | Relevance: 100%
- Jim Cramer emphasized the importance of portfolio diversification, highlighting Clorox (CLX) as a valuable offset to speculative AI stocks. Despite Clorox being one of the S&P 500's worst performers this year, Cramer noted its strong brands like Burt's Bees and Hidden Valley Ranch, and an attractive 4.72% dividend yield, suggesting it might be at a generational bottom.

**5. Clorox Scentiva Scented Bleach Adds Cherry Blossom & Peach Scent**
- Source: The Clorox Company | 20251217T030759 | Bullish | Relevance: 100%
- Clorox is expanding its Scentiva Scented Bleach line by introducing a new Cherry Blossom & Peach scent, aiming to combine powerful cleaning with a delicate fragrance. This innovation addresses consumer preference for pleasant scents in cleaning products, broadening the appeal of their bleach offerings. The new scent builds on the success of previous Scentiva products like Lavender & Jasmine, providing a "no compromises" solution for consumers.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Citigroup | $109 | $120 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($10.20M) |
| Sells | 11 ($0.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (-0.7%)
- Blackrock Inc.: 8.5% (-1.2%)
- State Street Corpora: 6.9% (+3.5%)
- Invesco Ltd.: 3.3% (+23.1%)
- Morgan Stanley: 2.6% (+18.3%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.3x requires aggressive growth execution.
3. Long-term trend broken: trading 20.5% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.35 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 44%, ROA 12%). Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($10.2M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.1B |
| Beta | 0.57 |
| 52W Range | $98.20 - $165.00 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.35 |
| Forward P/E | 14.7 |
| Current P/E | 16.6 |
| YoY Growth | 12.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.3% to -1.2% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.80x), long-term trend not supportive. OFD pattern: -MTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.23% (CS: 24) | Neutral |
| RSI_14 | 36.2 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 0.959x | Below |
| vs SMA50 | 0.915x | Below |
| vs SMA200 | 0.795x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.39
- **Stop Loss:** $94.47 (5.0% risk)
- **Target:** $104.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 144
- **Position Value:** $14,312.16
- **Portfolio %:** 14.31%
- **Risk Dollars:** $712.50
- **Risk Per Trade:** 0.71%
- **Modifiers:** L1 95% | L2 75% | Combined 0.71x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-03 (Est: $1.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.78 | $0.85 | +9.2% |
| 2025Q2 | $2.21 | $2.87 | +29.8% |
| 2025Q1 | $1.56 | $1.45 | -6.9% |
| 2024Q4 | $1.40 | $1.55 | +10.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*